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http://www.biomedcentral.com/1471-2261/13/73RESEARCH ARTICLE Open AccessCirculating microRNA expression profile and
systemic right ventricular function in adults after
atrial switch operation for complete transposition
of the great arteries
Clare TM Lai1, Enders KO Ng2, Pak-cheong Chow1, Ava Kwong2 and Yiu-fai Cheung1,3*Abstract
Background: Data on the use of circulating microRNAs (miRNAs) as biomarkers of cardiovascular diseases are
emerging. Little, however, is known on the expression profile of circulating of microRNAs in congenital heart
malformations with a systemic right ventricle that is prone to functional impairment. We aimed to test the
hypothesis that circulating miRNA profile is altered in patients late after atrial switch operation for complete
transposition of the great arteries (TGA) and further explored possible relationships between alteration of
circulating miRNAs and systemic ventricular contractility.
Methods: Circulating miRNA expression profiling of serum samples from 5 patients and 5 healthy controls was
performed. The results were validated in 26 patients and 20 controls using real-time quantitative reverse-transcription
polymerase chain reaction for candidate miRNAs with fold changes >3 by expression profiling. Systemic ventricular
myocardial acceleration during isovolumic contraction (IVA) was determined by colour tissue Doppler
echocardiography.
Results: Compared with controls, patients had significantly lower systemic ventricular IVA (p = 0.002). Of the 23
upregulated miRNAs identified by profiling, 11 were validated to be increased in patients compared with controls:
miR-16, miR-106a, miR-144*, miR-18a, miR-25, miR-451, miR-486-3p, miR-486-5p, miR-505*, let-7e and miR-93. Among
the validated 11 miRNAs, miR-18a (r = −0.45, p = 0.002) and miR-486-5p (r = −0.35, p = 0.018) correlated negatively
with systemic ventricular IVA for the whole cohort.
Conclusions: A distinct serum miRNA expression signature exists in adults with complete TGA after atrial switch
operation, with serum miR-18a and miR-486-5p being associated with systemic ventricular contractility.
Keywords: MicroRNA, Transposition of the great arteries, Atrial switch, Systemic ventricular functionBackground
MicroRNAs (miRNAs) are small non-coding single-
stranded RNAs with 19 to 24 nucleotides. These form
complementary pair with specific target mRNAs to
negatively regulate their expression via translational
repression or degradation [1]. While alteration of tissue* Correspondence: xfcheung@hku.hk
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reproduction in any medium, provided the ormiRNA expression has been well documented in malig-
nancies [2,3], the role of miRNA in cardiovascular devel-
opment [4], cardiac remodeling and heart failure [5,6], and
myocardial injury [7] is beginning to be recognized.
In determining the potential role of miRNAs in cardio-
vascular diseases, earlier studies have reported distinct
profiles of differential tissue miRNA expression in human
[8,9] and experimental models of heart failure [6,10].
Further cardiac tissue-based studies have provided evi-
dence of involvement of selective miRNAs in myocardial
hypertrophy [11,12], regulation of cardiac apoptosis
[13], regulation of cytoskeleton of cardiomyocytes andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activation [14,15], all of which contribute to adverse
cardiac remodeling.
Recent studies have shown that miRNAs released into
the blood stream are stable and measurable [16,17]. Im-
portantly, data in human subjects on the use of a signature
circulating miRNAs as novel markers of cardiovascular
diseases are emerging. Elevation of plasma cardiac-specific
miRNA-208a has been shown to be potentially useful for
early diagnosis of myocardial infarction [18], while plasma
miR423-5p has also been found to be increased in heart
failure patients with reduced left ventricular (LV) ejection
fraction [19]. Additionally, a signature circulating miRNA
expression profile has been reported in hypertensive
patients [20]. These encouraging data, albeit limited to
date, provide evidence that circulating miRNAs may be
potential biomarkers of cardiovascular diseases, in par-
ticular LV diseases.
Little, however, is known on the expression profile of
circulating microRNAs in congenital heart malformations
with a systemic right ventricle. In patients with complete
transposition of the great arteries (TGA) after atrial switch
operation, late systemic right ventricular (RV) dysfunction
is well documented [21,22]. There is further evidence to
suggest that deterioration of systemic RV function and
clinical status is progressive [22,23]. In this study, we
tested the hypothesis that the circulating miRNA profile is
altered in patients late after atrial switch operation and
further explored the relationships between alteration of
circulating miRNAs and systemic ventricular contractility.
Methods
Subjects
Twenty-six patients with complete TGA who had under-
gone Mustard or Senning procedure were recruited.
The following demographic and clinical variables were
collected: age at study, associated cardiac abnormalities,
age at and type of operation, duration of follow-up since
surgical repair, and current cardiac medications. Twenty
healthy subjects were recruited as controls. The Institu-
tional Review Board of The University of Hong Kong/
Hospital Authority West Cluster, Hong Kong, approved
the study and all study subjects gave written, informed
consent.
Serum collection and small RNA isolation
Blood obtained by venepuncture was centrifuged at
3000 rpm for 15 minutes immediately after collection.
The centrifuged serum was transferred to another tube
and re-spun once again to remove further debris. The
serum samples were stored at −80°C until assay. Total
RNA was extracted using Trizol LS reagent (Invitrogen,
Carlsbad, California, USA) and miRNeasy Mini Kit (Qiagen,
Hilden, California, USA) according to manufacturer’s in-structions with minor modifications [24]. Briefly, 500 μl
of serum was mixed with 1 ml Trizol LS reagent and
the aqueous phase of the mixture was transferred to a
new tube and centrifuged after addition of chloroform.
1.5 volume of absolute ethanol was added to the aqueous
phase and the mixture was applied into miRNeasy spin
column as per manufacturer’s instructions. RNA was
eluted with 30 μl RNase-free water. The concentration
of RNA was quantified by NanoDrop ND-1000 Spectro-
photometer (Nanodrop, Wilmington, Delaware, USA).
MiRNA profiling
To study differential miRNA expression in TGA patients
post atrial switch operation, we performed miRNA ex-
pression profiling of the serum samples from 5 patients
and 5 age- and sex-matched controls using TaqMan
Low Density Array Human MicroRNA Panel (Applied
Biosystems, CA, USA), which contains >754 well-estab-
lished miRNA assays including the respective reverse-
transcription primers, PCR primers, and TaqMan probe.
These 5 patients had the worst systemic RV function as
assessed by echocardiography. For each array assay,
80 ng/μl serum miRNA was used for the reverse-
transcription reaction with a pool of Megaplex RT
primers. TaqMan-based qPCR profiling was performed
using TaqMan Universal PCR Master Mix (Applied
Biosystems) in ABI PRISM 7900 HT system (Applied
Biosystems) according to the manufacturer’s instruc-
tions. U6 small nuclear RNA in the array was selected
as the internal normalization transcript. The Δ cycle of
threshold (Ct) was calculated by subtracting the averaged
Ct values of U6 from the Ct values of the miRNA of
interest. ΔΔCt was then calculated by subtracting ΔCt
of the control from ΔCt of the sample. Fold change of
the miRNA was calculated by the equation: 2−ΔΔCt. Up-
and down-regulation of miRNAs with fold changes >3
were selected for validation in the entire patient cohort.
Real-time quantitative reverse-transcription polymerase
chain reaction
To validate the findings of miRNA profiling, we measured
the expression levels of differentially expressed miRNAs
using Real-Time Quantitative Reverse-Transcription Poly-
merase Chain Reaction (qRT-PCR) in all of the 26 patients
and 20 controls. SYBR green qRT-PCR assay was used
for individual miRNA quantification [24]. Briefly, 30 ng
of serum RNA was polyadenylated by poly(A) polymer-
ase and reversely transcribed using miScript Reverse
Transcription Kit (Qiagen) according to manufacturer’s
instructions. Real-time qPCR was performed using
miScript SYBR Green PCR Kit (Qiagen) in ABI PRISM
7900 Real-time PCR system (Applied Biosystems). Ampli-
fication was performed with the miScript Universal pri-
mer provided by manufacturer and the miRNA-specific
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for qRT-PCR were listed in Additional file 1: Table S1.
The amplification profile was 95°C for 15 minutes,
followed by 45 cycles of 94°C for 15 seconds, 55°C for
30 seconds, and 70°C for 30 seconds. At the end of the
PCR cycles, melting curve analyses were performed.
The expression levels of miRNAs were normalised to
U6 small nuclear RNA (RNU6B) level [24]. The fold
change of the miRNA was calculated as aforementioned.
Echocardiographic assessment
Transthoracic echocardiography was performed using
the Vivid 7 ultrasound system (General Electric Vingmed
Ultrasound, Horten, Norway). Echocardiographic record-
ings were made in three cardiac cycles and the average
was used for statistical analysis. Offline analyses were
performed using the EchoPAC software (General Electric,
Horten, Norway). Colour tissue Doppler echocardiography
was used to measure the relative load independent
index of systolic function, myocardial acceleration dur-
ing isovolumic contraction (IVA) [25], of the systemic
ventricle. Colour-flow mapping was used for the assess-
ment tricuspid regurgitation and baffle stenosis or leakage
in patients.
Statistical analysis
Data are presented as mean ± standard deviation or me-
dian (range) as specified. Demographic variables and echo-
cardiographic parameters were compared using unpaired
Student’s t test and Fisher’s exact test where appropriate.
Serum miRNA expression levels between patients and
controls were compared using Mann–Whitney test.Table 1 Demographic and clinical characteristics of patients a
Microarray
Patients (n = 5) Controls (n
Age at study (years) 26.5 ± 5.1 24.5 ± 6.3
Gender (M:F) 3:2 3:2
BMI (kg/m2) 19.9 ± 1.5 23.3 ± 3.9
BSA (m2) 1.66 ± 0.09 1.77 ± 0.22
Age at surgery (years) 2.24 ± 2.26 -
Type of operation (Mustard: Senning) 1:4 -
Closure of VSD 2 -
Medical treatment (n) (2) -
- ACEI 2 -
- ARB 2 -
- furosemide 1 -
- spironolactone 1 -
- aspirin 1 -
- digoxin 0 -
ACEI: = angiotensin-converting enzyme inhibitors, ARB: = angiotensin II receptor bloc
quantitative reverse-transcription polymerase chain reaction, VSD: = ventricular septRelationships between logarithmically transformed serum
miRNA levels and systemic ventricular IVA were deter-
mined by Pearson correlation analysis. All p values are
two-sided and a p value < 0.05 was considered statistically
significant. All statistical analyses were performed using
SPSS 16.0 (SPSS Inc., Chicago IL, USA).Results
Subject characteristics
The demographic and clinical characteristics of all sub-
jects are summarized in Table 1. Of the 26 patients, 22
had undergone Senning operation while 4 had Mustard
procedure. Eight patients had closure of an associated
ventricular septal defect. At the time of study, 5 patients
were taking cardiac medications and were in New York
Heart Association functional class II. The remaining 21
patients were in functional class I. There were no signifi-
cant differences in age, sex distribution, and body size
between patients and controls for both the cohort in
the profiling study and the entire cohort included in
the validation part (all p > 0.05).Cardiac status in patients
Tricuspid regurgitation was severe in 1 patient, trivial to
mild in 19, and absent in 6. Mild baffle leak was found
in 1 patient, while mild subpulmonary stenosis was noted
in 2. History of cardiac arrhythmias was documented in 4
patients, with 1 each having sinus node dysfunction, first
degree heart block, atrial flutter, and infrequent ventricular
ectopics. All patients were in sinus rhythm at the time of
study. Compared with controls, patients had significantlynd controls
qRT-PCR validation
= 5) p Patients (n = 26) Controls (n = 20) p
0.60 25.3 ± 3.2 25.0 ± 4.3 0.82
1.0 17:9 11:9 0.82
0.12 21.8 ± 3.3 21.6 ± 3.3 0.84
0.30 1.67 ± 0.14 1.70 ± 0.21 0.57
1.90 ± 2.26 -
4:22 -
8 -
(5) -
4 -
3 -
1 -
1 -
1 -
1 -
kers, BMI: = body mass index, BSA: = body surface area, qRT-PCR: = real-time
al defect.
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1.45 ± 0.39 m/s2, p = 0.002).Identification of differentially expressed serum miRNAs
in patients
Serum miRNA expression profiling was performed using
serum samples from 5 patients and 5 controls matched
for age and sex (Table 1). The level of RNU6B used for
normalization was similar between patients and controls
(32.3 ± 0.4 vs 32.4 ± 0.5, p = 0.54). The levels of serum
miRNAs differed between patients and controls as illus-
trated in the heat map (Figure 1). One hundred miRNAs
with fold change >1 and RNU6B levels are shown in
Additional file 2: Table S2. Using a 3-fold expression
difference as a cut-off level, 23 miRNAs were found to
be significantly up-regulated and 1 miRNA significantly
down-regulated in patients compared with controls
(Table 2). As miR-505* was expressed only in patients,
the absolute fold-change could not be calculated.Figure 1 Profiling of serum microRNAs in 5 patients after atrial switch
healthy control subjects. miRNAs with fold changes >2 are shown in the
y-axis. Colour scale is shown on the top with green indicating downregulaLarger sample size validation
To validate the profiling results, qRT-PCR was performed
to measure the serum expression levels of the 24 miRNAs
in 26 patients and 20 controls. For the whole cohort, there
was similarly no significant difference in RNU6B level
between patients and controls (28.7 ± 1.3 vs 28.8 ± 1.6,
p = 0.79). Among the 23 up-regulated miRNAs, 11 were
significantly elevated in patients compared with con-
trols: miR-16, miR-106a, miR-144*, miR-18a, miR-25,
miR-451, miR-486-3p, miR-486-5p, miR-505*, let-7e
and miR-93 (Figure 2). However, down-regulation of
miR-494 was not confirmed by qRT-PCR.
Factors associated with up-regulated serum miRNAs
For the whole cohort, IVA correlated negatively with
serum miR-18a (r = −0.45, p = 0.002) and miR-486-5p levels
(r = −0.35, p = 0.018) (Figure 3). Furthermore, serum levels
of miR-18a and miR-486-5p were positively correlated
(r = 0.575, p < 0.001) (Additional file 3: Figure S1). None
of validated miRNAs were associated with baselineoperation for transposition of the great arteries (TGA) and 5
heat map. The expression of miRNA is hierarchically clustered on the
tion and red upregulation.
Table 2 Up- and down-regulated miRNAs as defined by
fold changes >3 by expression profiling in patients
compared with control subjects
MicroRNA MirBase no Average fold change
miR-505* MIMAT0004776 ↑ in patients only
miR-144* MIMAT0004600 15.08
miR-18a MIMAT0000072 14.9
miR-486-3p MIMAT0004762 8.67
miR-20a MIMAT0000075 7.53
miR-451 MIMAT0001631 6.04
miR-486-5p MIMAT0002177 5.45
miR-374a MIMAT0000727 5.20
miR-16 MIMAT0000069 5.09
miR-375 MIMAT0000728 4.80
miR-331-3p MIMAT0000760 4.50
Hsa-let-7e MIMAT0000066 4.47
miR-25 MIMAT0000081 4.01
miR-93* MIMAT0004509 3.76
miR-93 MIMAT0000093 3.62
miR-92a MIMAT0000092 3.58
miR-30b MIMAT0000420 3.56
miR-19a MIMAT0000073 3.53
miR-17-5p MIMAT0000070 3.39
miR-106a MIMAT0000103 3.28
miR-30d MIMAT0000245 3.22
miR-574-3p MIMAT0004795 3.18
miR-19b MIMAT0000074 3.08
miR-494 MIMAT0002816 0.27
* is the notation for some of the miRs.
↑ in patients only’ literally ‘increased in patients only.
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of which correlated with body mass index (r = 0.32, p =
0.03) (Additional file 4: Table S3).
Discussion
The present study demonstrates a distinct serum miRNA
expression signature in adult patients with complete TGA
after atrial switch operation. Expression profiling of cir-
culating miRNA revealed significant upregulation of 23
miRNAs and downregulation of 1 miRNA, while only 11
of the upregulated miRNAs were validated in a larger
patient cohort using qRT-PCR. Importantly, significant
negative correlations were identified between systemic
ventricular IVA, a relative load-independent index of
systemic ventricular contractility, and two miRNAs
miR-18a and miR-486-5p.
There is paucity of data on the expression profile of
circulating microRNAs in congenital heart malformations
with a systemic right ventricle. In the only study publishedto date, Tutarel et al. showed no difference in the levels of
circulating miR-423-5p between adults after atrial repair
of TGA and healthy subjects [26]. To our knowledge,
this is the first study using expression profiling followed
by validation of differentially expressed serum miRNAs to
explore potential alteration of circulating miRNA profile
in patients late after atrial switch operation.
Of the 11 validated miRNAs, several had been reported
to associate with cardiovascular and cerebrovascular
diseases. Up-regulation of peripheral blood let-7e has
been shown in large and small artery stroke, cardio-
embolic stroke and stroke with undetermined causes,
while expression of miR-16, miR-106a, miR-25 and miR-
93 were found to be differentially increased in patients
with small artery stroke only [27]. In hypertensive patients,
plasma expression of let-7e has been demonstrated to
be elevated in profiling studies [20]. In a rodent model
of pulmonary hypertension, miR-451 in lung tissues
showed a strong upregulation in hypoxic samples [28],
while in children with aortic stenosis undergoing aortic
valve replacement, differential upregulation of ventricu-
lar let-7e and miR-93 has been reported [8].
The differentially expressed circulating miRNAs iden-
tified in the present study appear to be involved in bio-
logic processes that are of relevance to our patients:
angiogenesis (miR-16 and miR-18a) [29,30], hypoxia
regulation (let-7e, miR-16, miR106a and miR-93) [31],
and apoptosis and cell cycle control (miR-16) [32,33]. In
this regard, it is worthwhile noting that abnormal myo-
cardial perfusion and reduced coronary flow reserve
[34,35] are well documented in patients after atrial switch
operation. It would also be interesting to determine the
level of vascular endothelial growth factors in patients in
future studies. Our recent finding of increased circulating
annexin A5 lends support to possible increased apoptotic
process in these patients [36] Gene prediction program-
mes [37] identify biological pathways of cardiac signifi-
cance, which include MAPK signaling [38], Wnt signaling
[39], and TGF beta signaling [40].
Progressive systemic RV dysfunction in patients after
Senning and Mustard operation remains an important
issue of concern [21,22]. MicroRNAs may play a role in
LV remodeling process through regulating the gene
networks that modulate cardiomyocyte apoptosis and
myocardial fibrosis [41]. While the precise mechanism
of systemic RV dysfunction remains elusive, our novel
findings of negative relationships between expression of
serum miR-18a and miR-486-5p and systemic ventricular
IVA suggests a possible role of dysregulated microRNAs.
The contractile apparatus of the systemic right ventricle
may potentially be jeopardized by ischaemia [34,35] and
apoptosis [36]. miR-18a has been shown to downregulate
Ataxia Telangiectasia Mutated (ATM) expression and
reduce DNA damage repair ability [42]. Further studies
Figure 2 Validation of serum microRNAs levels in patients and controls. Levels of miRNA expression are normalized to RNU6B level.
Horizontal line represents the median.
Lai et al. BMC Cardiovascular Disorders 2013, 13:73 Page 6 of 9
http://www.biomedcentral.com/1471-2261/13/73have unveiled a protective role ATM in cardiac apoptosis
[43]. There are also suggestions that our other validated
candidate miR-486-5p, which is enriched in cardiac and
skeletal muscles, may have a role in modulating cardiac
contractile function [44]. Overexpression of miR-486
has been reported to enhance muscle phosphoinositide-3-
kinse (PI3K)/Akt signaling by reducing the upstream
negative regulator, phosphatase and tensin homolog
(PTEN) [44]. Of relevance is the demonstration of de-
creased cardiac contractility with pharmacological in-
hibition of PTEN and in cardiac muscle specific PTEN
knockout mice [45,46]. Furthermore, chronic overex-
pression of Akt has been shown to cause maladaptive
hypertrophy of the left ventricle with dilation andcontractile dysfunction [47]. Although we have not deter-
mined the levels of brain natriuretic peptide, a biomarker
of ventricular dysfunction, in the present study, we [48]
and others [49] have reported previously the elevation
of brain natriuretic peptide in patients after atrial repair
with impaired systemic RV function.
With regard to the cardiac extracellular matrix, the
cardiomyocyte-derived miR-18a has been reported to
play a role in age-related heart failure through modulation
of matrix protein levels [50]. Transfection of miR-25,
another of our validated miRNA candidate, in cardiac
fibroblast has also been demonstrated to decrease col-
lagen gene expression [51]. Indeed, our recent findings
of increased tumour necrosis factor and absence of
Figure 3 Scatter plots showing negative correlation between systemic ventricular myocardial acceleration during isovolumic
contraction (IVA) and (A) serum miR-18a and (B) miR-486-5p expressions. Closed and open dots represent patients and
controls, respectively.
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thesis in patients with TGA after atrial switch operation
implicate reduced myocardial collagen synthesis [36].
Hence, reduction of matrix tensile strength may be a
cause of progressive RV dilation in post Senning and
Mustard patients.
Taken together, our novel finding of a distinct circulat-
ing miRNA profile sheds light on the pathogenesis of
systemic RV dysfunction in patients after atrial switch
operation from an entirely new perspective. There is no
doubt, however, that the findings are preliminary and that
the molecular mechanisms of upregulation of circulating
miRNAs in our patients require further investigations. In
this regard, inclusion of additional patient cohorts with
subpulmonary right ventricles operating under relatively
normal pressure, as in TGA patients after arterial switch
operation, and increased pressure, as those with severe
pulmonary stenosis, may shed more light on the under-
lying mechanism. Another important limitation of the
present study is that we cannot ascertain the source in our
patients of the upregulated circulating miRNAs, which
may occur as a result of cellular damage or secretion [52].
Nonetheless, De Rosa et al. have recently provided convin-
cing evidence of the cardiac source of circulating miRNAs
associated with acute coronary syndromes [53]. Further-
more, despite the undetermined source, circulating miR
NAs may function as potential paracrine mediator of
cardiovascular disease [54].
Conclusion
In conclusion, the present study provides the first evi-
dence of an altered circulating miRNA expression profile
in adult congenital heart patients with a systemic rightventricle after atrial switch operation. While we have
validated the expression profiling results independently
in a bigger cohort of subjects, these preliminary data
need to be confirmed in a larger clinical population. Given
the demonstrable relationships between serum miR-18a
and miR-486-5p expressions and systemic ventricular
contractility, further studies are warranted to explore
the potential usefulness of circulating miRNAs as bio-
markers for development of systemic RV dysfunction.
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